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PredictorsObjectives: We aim to determine influenza vaccination uptake among people with diabetes included in
the MADIABETES cohort study in order to identify predictors of uptake and to analyze reasons for adher-
ence and non-adherence with vaccination.
Methods: Using data from the MADIABETES Study we conducted a retrospective case record form based
study without controls. We included outpatients with type 2 diabetes mellitus. Information was obtained
from computerized clinical records and by telephone survey.
Methods: The main dependent variables were influenza vaccination uptake in the year 2013 and the
reason for receiving or refusing vaccination.
Results: Overall, 65.7% had received the influenza vaccine in 2013. The mean number of influenza vacci-
nes received from 2007 to 2013 was 3.24 (SD1.15), although 19.23% had not received any influenza vac-
cine and 23.3% had been vaccinated against pneumococcus. The variables that increased the probability
of being vaccinated were inclusion in the age-based recommendation (P60 years), having a chronic res-
piratory disease, previous pneumococcal vaccination, higher number of visits to the general practitioner,
higher number of influenza vaccines, and longer time since diabetes diagnosis. A higher mean glycated
haemoglobin value in 2013 was associated with a reduced probability of vaccination.
Results: Most patients (90%) agreed to be vaccinated following their physician’s advice because of their
age or their chronic conditions. The most common reason for refusal among men was the belief that they
were not at risk (41.6% vs. 29.79% in women); the most common reason for refusal among women was
fear of adverse reactions (32.53% vs. 20.23% in men).
Conclusions: The uptake of influenza vaccination among diabetic patients in the present study was below
desirable levels. The main barrier to vaccination was lack of knowledge regarding the need for and risks
and advantages of influenza vaccination. Healthcare professionals should educate and encourage influ-
enza vaccination among people with diabetes.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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During the last few decades, diabetes has become a major pub-
lic health problem because of its increasing prevalence worldwide
[1]. Recent data from a Spanish population-based study reported a
prevalence of diabetes of 13.8% [2]. Type 2 diabetes mellitus
(T2DM) is the most prevalent form of diabetes. The prevalence of
T2DM has increased in parallel with cultural and societal changes
to the extent that over 90% of diabetic adults in high-income coun-
tries have T2DM [1–3].
People with diabetes are more likely to die or be admitted to
hospital as a result of influenza than healthy individuals [3,4].
Several observational studies of the effectiveness of the influ-
enza vaccine in diabetes patients [5–8] found that vaccination
reduced diabetes-related hospital admissions during epidemics
and that influenza-related mortality decreased [5–10].
Annual influenza vaccination of people with T2DM is recom-
mended by the World Health Organization, the Centers for Disease
Control and Prevention, the European Union, and the main dia-
betes associations [3,11–13]. In Spain, the public health authorities
recommend annual influenza vaccination for patients with T2DM,
and the vaccine is free for vulnerable groups [14].
Despite the broad consensus on recommending influenza vacci-
nation for people with T2DM, coverage varies across different geo-
graphical locations, and, in most cases, the percentage of those
who receive the vaccine is below desirable levels [15–22]. In devel-
oped countries, coverage values are around 60–70%, with some
studies showing decreasing proportions in recent years, mainly
after the H1N1 influenza pandemic [15–22].
In Europe, very few countries reached the European Union
Council recommendation set in 2009, which advises vaccination
in 75% of at-risk populations [13].
In Spain, data from health records suggest that uptake is around
50%, rising to approximately 60% if health surveys are used [21,22].
The patient-related and health care–related factors associated
with influenza vaccination in T2DM patients are very complex
[17,20,22–27]. Predictors of uptake include sociodemographic
characteristics, comorbid conditions, diabetes-related clinical vari-
ables, lifestyle, adherence to preventive practices, and use of health
care services. Older age and comorbidity are the two factors most
frequently associated with influenza vaccination. However, results
are sometimes contradictory, thus necessitating further investiga-
tion in this population [17,20,22–27].
To our knowledge, no previous study has assessed perceptions
of influenza vaccination among people with T2DM in Spain. The
few studies conducted elsewhere show that the most common rea-
sons for refusing the influenza vaccine are insufficient knowledge
about the need for the vaccine, low perceived susceptibility to
influenza, low perceived severity of infection, concerns about
potential side effects, and doubts about the vaccine’s effectiveness
[23,24,26,27].
The objectives of the present study were as follows: (i) to assess
the level of influenza vaccination among people with diabetes
included in a primary care–based cohort (MADIABETES) in the year
2013; (ii) to identify predictors of vaccination uptake; and (iii) to
analyze reasons for adherence and non-adherence to the
recommendations.2. Materials and methods
2.1. Study population and design
The Madrid Diabetes Study (MADIABETES Study) is a prospec-
tive cohort study of 3443 T2DM outpatients which has been
described in detail elsewhere [28]. Briefly, patients were recruitedfrom 56 primary care centers in the metropolitan area of Madrid
(Spain). Data were collected by GPs at the baseline visit (2007)
and annually during the follow-up period (2008–2013). These data
were recorded using electronic case report forms. The last-
observation-carried-forward method was used to impute missing
values for patients with incomplete data during the follow-up
period.
Using the MADIABETES Study database we conducted a retro-
spective case record form based study without controls.
The inclusion criteria were age P25 years and a confirmed
diagnosis of T2DM. The exclusion criteria were T1DM and being
homebound. Of the 3443 individuals followed-up until 2013, 553
died during 2007–2013, and information was missing for 602.
The final sample comprised 2288 participants.
2.2. Information sources and study variables
Information was obtained from two sources, namely, computer-
ized clinical records (CCR) and the results of a specific telephone
survey conducted by trained interviewers from January to Decem-
ber 2013.
We used the latest available data in the computerized clinical
record system and always for the year 2013. The variables col-
lected from the CCR system were as follows:
1. Influenza vaccination uptake in the year 2013, influenza vacci-
nation uptake during the previous six years, and pneumococcal
vaccination at any time from 2007 to 2013.
2. Sociodemographic characteristics including age, gender, marital
status (married vs. not) and educational level (primary educa-
tion or below vs. secondary or over). Age was categorized into
groups according to the age that the influenza vaccine recom-
mendation becomes universal in Madrid (P60 years).
3. Duration of diabetes and diabetes-related complications includ-
ing history of heart disease (myocardial infarction, angina, and
congestive heart failure), cerebrovascular disease (stroke, tran-
sitory ischemic attack), nephropathy, neuropathy, retinopathy,
amputations, peripheral vascular disease, and diabetic foot.
The variable ‘‘any diabetes complications” included patients
with none versus those with one or more complications.
4. History of other comorbid conditions such as obesity, high
blood pressure, chronic respiratory diseases (asthma and
COPD), depression, and cancer.
5. Pharmacological treatment prescribed, including insulin ther-
apy, current blood pressure medications and lipid-lowering
medications.
6. Clinical monitoring indicators including glycated haemoglobin
(HbA1c), systolic blood pressure, diastolic blood pressure, total
cholesterol, and body mass index. If these parameters were
measured more than once in the year 2013, the mean was cal-
culated and analyzed.
7. Number of visits to the GP in the year 2013.
8. A variable named ‘‘Indication for influenza vaccination other
than T2DM” has been created and analyzed. This variable
included those patients that suffer one or more of the following
chronic conditions: heart diseases, cerebro-vascular disease,
nephropathy, cancer and chronic respiratory disease.
The telephone survey included questions regarding influenza
vaccination, lifestyle, mental health, and quality of life.
All patients were asked if they had been vaccinated against
influenza in the latest campaign. The reasons for receiving the vac-
cination were as follows: (i) recommended by a physician because
of age; (ii) recommended by a physician because of chronic condi-
tions; (iii) vaccination in the workplace; (iv) own request; (v)
other; and (vi) do not know.
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lowing options: (i) not recommended by a health care worker
(HCW) or health authorities; (ii) patient does not consider him/
herself at risk; (iii) patient believes the vaccine is not effective;
(iv) fear of adverse reactions; (v) belief that the vaccine can trans-
mit the influenza virus; (vi) belief that influenza is a benign illness;
(vii) access difficulties (lack of time, distance to the health centre);
(viii) other; (ix) do not know. Only one option could be marked in
both cases.
Lifestyle data included physical exercise (none, little, regular/
high), usual alcohol consumption (none vs. any), and tobacco use
(never smoker, ex-smoker, and current smoker).
Health status was measured using the SF-36 questionnaire,
which yields two summary scores, namely, the Physical Compo-
nent Summary (PCS) and the Mental Component Summary (MCS).
2.3. Statistical analysis
Descriptive data were expressed as mean and standard devia-
tion. Normally distributed continuous variables were compared
using the t test. Non-normally distributed variables were com-
pared using the Mann-Whitney test. Categorical variables were
compared using the chi-square test.
Multivariate logistic regression models were constructed to
identify variables that were independently associated with vaccine
uptake among patients with T2DM. We report adjusted odds ratios
(ORs) with their respective 95% confidence intervals (95% CI). Vari-
ables that were statistically significant in the bivariate analysis and
those shown to be predictors in previous studies were included in
the multivariate analysis. Given the multiple testing the results of
the multivariate regression should be interpreted for significance
using the Bonferroni correction.
All calculations were performed using SPSS v.21.0 for Windows
and STATA v11.1SE. Significance was set at p < 0.05 (two-tailed).
2.4. Ethical aspects
The study was approved by the Institutional Review Board of
the Ramón y Cajal Hospital (Madrid) and conducted in accordance
with the principles of the Declaration of Helsinki. All patients gave
their written informed consent to participate in the study.3. Results
Of the initial 3443 patients (January 2007), a total of 2890 were
alive before the start of the survey (January 2013) and 2288 agreed
to the interview (participation rate, 79.2%).
The computerized clinical records showed that nearly two-
thirds of patients with T2DM (1504/2288, 65.7%) had received
the influenza vaccine in the year 2013. Mean age was 70.3 years
(SD 10.4) and 52% were men. Women were significantly (T student
test = 7.76; p < 0.001) older than men (71.65 vs. 69.04 years).
The mean number of influenza vaccines received per individual
in the period 2007–2013 was 3.24 (SD 1.15), and 23.3% had been
vaccinated against pneumococcus. The proportion of diabetic
patients who had not received any influenza vaccine over the
seven-year follow-up period was 19.23%.
Table 1 shows the distribution of influenza vaccination in the
year 2013 according to sociodemographic characteristics, lifestyle,
comorbid conditions, previous vaccination, visits to the GP, and
quality of life.
Patients who received the influenza vaccine tended to be older
and married, with a lower educational level and more healthy
behaviors (never smoked and not habitual consumers of alcohol).
They also seemed to have more comorbid conditions (high bloodpressure and chronic respiratory diseases) and reported a worse
quality of life. Patients with T2DM who had received the pneumo-
coccal vaccine and a higher number of influenza vaccines during
previous years were vaccinated in a significantly higher propor-
tion. Vaccinated patients had visited their GP during the previous
year a mean of 2.5 times more than unvaccinated patients.
Table 2 shows the distribution of influenza vaccination accord-
ing to complications of T2DM, pharmacological treatments, dura-
tion of diabetes, and clinical monitoring indicators. Vaccination
coverage was higher among diabetic patients who had any chronic
diabetic complication and, specifically, among those who had heart
disease, neuropathy, retinopathy, amputations, or peripheral vas-
cular disease. The mean time since diagnosis of diabetes was
higher in vaccinated patients. Conversely, mean glycated haemo-
globin, mean diastolic blood pressure, and mean total cholesterol
were lower in vaccinated patients. As can be seen in Table 2 those
with an indication for influenza vaccination other than T2DM were
vaccinated in a higher proportion than those without it (68.79% vs.
62.41%; p value < 0.001).
The covariates independently associated with receiving the
influenza vaccination in the final multivariate model are shown
in Table 3. The variables that increased the probability of being
vaccinated were inclusion in the age-based recommendation, that
is, P60 years (OR, 2.50; 95%CI, 1.82–3.44), having a chronic respi-
ratory disease (OR, 1.52; 95%CI, 1.02–2.30, p value = 0.011, alpha p
value with Bonferroni correction = 0.007), previous pneumococcal
vaccination (OR, 2.54; 95%CI, 1.83–3.55), higher number of visits
to the GP in 2013 (OR, 1.05; 95%CI, 1.01–1.09), higher number of
influenza vaccinations (OR, 1.29; 95%CI, 1.10–1.57), and longer
time since diagnosis of diabetes (OR, 1.03; 95%CI, 1.01–1.06).
Finally, a higher mean value of glycated haemoglobin in 2013
was associated with a reduced probability of vaccination that year
(OR, 0.83; 95%CI, 0.75–0.93).
Table 4 shows the reasons for receiving or not receiving the
influenza vaccination according to gender.
Most patients (both genders) received the vaccination following
the advice of their primary care physician because of their age or
because of their chronic conditions. Both reasons accounted for
around 91% of vaccinations in men and over 95% in women.
Patients requested the vaccination on their own account far less
frequently (3.03% in men and 1.29% in women).
The reasons for refusal differed by gender (p < 0.01). In men, the
most common reason was not considering oneself at risk (41.6%
and 29.79% in women); in women, the most common reason was
fear of adverse reactions (32.53% vs. 20.23% in men).
Other reasons that show insufficient knowledge about the vac-
cine were much less frequent and include belief that the vaccine is
not effective (8.71%), belief that the vaccine can transmit influenza
(2.18%), and belief that influenza is a benign illness (2.95%).4. Discussion
The main result of our investigation is that one-third of T2DM
patients included in the study population were not vaccinated
against influenza in 2013. Furthermore, one-fifth of patients had
not been vaccinated during the previous seven campaigns.
In Europe, the highest reported vaccination coverage was in the
Netherlands, where an observational longitudinal study based on
electronic medical records found that influenza vaccination cover-
age in persons with diabetes decreased significantly from 85.1% in
the 2008 season to 74.7% in the 2013 season [15]. Other European
countries such as France, the United Kingdom, and Ireland have
coverages of around 60–70% in the diabetic population [16–18].
Similar rates have been reported in the US and Canada [19,20]. In
a prospective cohort study performed in Alberta, Canada between
Table 1
Distribution and influenza vaccination in 2013 according to socio-demographic characteristics, lifestyles, comorbid conditions, previous vaccination, GP visits and quality of life.
Influenza vaccine in 2013
N = 2288 No N (%) Yes N (%) Coverage% p-value
Gender Men 432(55.1) 758(50.4) 63.7 0.033
Women 352(44.9) 746(49.6) 67.94
Age groups 25–49 Years 46(5.87) 28(1.86) 37.84 <0.001
50–59 Years 160(20.41) 145(9.64) 47.54
60–69 Years 253(32.27) 374(24.87) 59.65
70–79 Years 202(25.77) 611(40.63) 75.15
80 years and over 123(15.69) 346(23.01) 73.77
Age recommendation (P60 years) No 227(28.95) 193(12.83) 45.95 <0.001
Yes 557(71.05) 1311(87.17) 70.18
Marital status Married 538(68.6) 1036(68.9) 65.8 0.006
Other 246(31.4) 468(31.1) 65.3
Educational level Primary or less 471(60.38) 1016(68.23) 68.33 <0.001
Secondary or over 309(39.62) 473(31.77) 60.49
Physical exercise None 100(12.94) 156(10.45) 60.94 0.025
Little 598(77.36) 1226(82.12) 67.21
Regular/high 75(9.70) 111(7.47) 59.68
Alcohol consumption No 484(61.73) 999(66.42) 67.36 0.026
Yes 300(38.27) 505(33.58) 62.73
Tobacco use Never smoker 299(38.14) 678(45.08) 69.4 <0.001
Ex-smoker 356(45.41) 666(44.28) 65.17
Current smoker 129(16.45) 160(10.64) 55.36
High blood pressure No 204(26.02) 264(17.55) 56.41 <0.001
Yes 580(73.98) 1240(82.45) 68.13
Depression No 700(89.29) 1354(90.03) 65.92 0.579
Yes 84(10.71) 150(9.97) 64.1
Cancer No 677(87.02) 1272(84.57) 65.26 0.117
Yes 101(12.98) 232(15.43) 69.67
Chronic respiratory disease No 716(91.33) 1291(85.84) 64.32 <0.001
Yes 68(8.67) 213(14.16) 75.8
Obesity No 400(51.02) 758(50.4) 65.46 0.778
Yes 384(48.98) 746(49.6) 66.02
Previous pneumococcal vaccination No 672(85.71) 1084(72.07) 61.73 <0.001
Yes 112(14.29) 420(27.93) 78.95
Number of influenza vaccines. Mean [SD]a 1.31[1.81] 4.3[1.98] NA <0.001
Number of visits to the GP in 2013 Mean [SD] 10.89[6.94] 13.36[8.5] NA <0.001
SF-36 physical component summary Mean [SD] 41.23[11.22] 38.63[11.65] NA <0.001
SF-36 mental component summary. Mean [SD] 51.35[9.69] 52.13[8.95] NA 0.071
NA. Not applicable.
a Number of influenza vaccines per person from 2007 to 2013.
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having been vaccinated in the previous year [15]. According to the
2011 Behavioral Risk Factor Surveillance System survey in the US,
the influenza vaccination coverage rate was 60.2% among persons
with diabetes aged P18 years and 66.3% in those aged P65 years
[25].
In 2011 in Spain, the estimated coverage among people with
diabetes aged 15 or over was 57.1% when estimated using the
2011 Spanish National Health Survey and 51.4% when estimated
using primary care electronic clinical records [21]. According to
previous Spanish National Health Surveys, which have reported
values of around 60% for all surveys conducted since the year
2003, vaccination uptake had not markedly improved [22].
In our study, the frequency of influenza vaccination increased
sharply with age from only 37.8% in those aged 25–49 years to
75.2% in those aged 70–79 years. The positive association between
vaccine coverage and age is almost constant in the diabetic popu-
lation [17,21–27].
The results of the multivariate model showed that if we use
60 years as the cut point, persons aged P60 years were 2.5 times
more likely to be vaccinated than those under this age. In our opin-
ion, such a large increase is a consequence of the fact that age-
based strategies are more effective for increasing uptake than
high-risk strategies [29,30].
Chronic respiratory conditions were a positive predictor of vac-
cine uptake among diabetic adults in the study, even if the p value
was not significant if the Bonferroni correction is used. In Canada,respiratory disease was associated with a 1.39-fold (95%CI
1.07–1.81) greater coverage in patients with T2DM [20]. Previous
investigations have found that patients that suffer a higher number
of influenza vaccine indications have significantly higher vaccina-
tion coverage than those with only one condition. Possible expla-
nations for this are that they visit more frequently the GP and
therefore have a greater chance to be vaccinated, that patients with
more chronic conditions make the GP, specialists and nurses be
more aggressive recommending the vaccine or that patients with
more chronic conditions are themselves more conscious of the
necessity to be vaccinated [18–22].
As expected, previous pneumococcal vaccination was highly
predictive of uptake (OR 2.54; 95%CI 1.83–3.55): in Madrid, vacci-
nation is universally recommended for people agedP60 years and
people with T2DM regardless of their age [31]. Achtymichuk et al.
[20] found that history of pneumococcal vaccination increased
influenza vaccine uptake almost 12-fold (aOR 11.67, 95%CI 9.13–
14.9).
Our results are consistent with those of studies suggesting that
previous influenza vaccination was a predictor of subsequent vac-
cination [26,24]. It has been argued that once individuals have
adopted a particular preventive health behavior, they are likely
to adhere to that behavior over time [26,32,33].
The two clinical characteristics that were positively related to
vaccination uptake in our study were longer duration of diabetes
and lower mean glycated haemoglobin. Both variables have been
reported in persons with T2DM [17,18,27].
Table 2
Distribution and influenza vaccination in 2013 according to diabetes complications, pharmacological treatments, duration of diabetes, and clinical monitoring indicators.
Influenza vaccine in 2013
N = 2288 No N (%) Yes N (%) Coverage% p-value
Heart diseases No 595(75.89) 1081(71.88) 64.49 0.039
Yes 189(24.11) 423(28.13) 69.11
Cerebro-vascular disease No 708(90.31) 1348(89.63) 65.56 0.610
Yes 76(9.69) 156(10.37) 67.24
Nephropathy No 633(80.74) 1203(79.99) 65.52 0.668
Yes 151(19.26) 301(20.01) 66.59
Neuropathy No 722(92.09) 1312(87.23) 64.5 <0.001
Yes 62(7.91) 192(12.77) 75.59
Retinopathy No 678(86.48) 1241(82.51) 64.67 0.014
Yes 106(13.52) 263(17.49) 71.27
Amputations or peripheral vascular disease No 725(92.47) 1314(87.37) 64.44 <0.001
Yes 59(7.53) 190(12.63) 76.30
Diabetic foot No 678(86.48) 1268(84.31) 65.16 0.167
Yes 106(13.52) 236(15.69) 69.01
Any diabetes complications No 391(49.87) 632(42.02) 61.78 <0.001
Yes 393(50.13) 872(57.98) 68.93
Indication for influenza vaccination other than T2DM No 412(52.55) 684(45.48) 62.41 <0.001
Yes 372(31.21) 820(68.79) 68.79
Insulin therapy No 413 (90.77) 842 (89.38) 67.09 0.422
Yes 42 (9.23) 100 (10.62) 70.42
Current blood pressure medications No 278(61.1) 533(56.58) 65.72 0.109
Yes 177(38.9) 409(43.42) 69.8
Current cholesterol-lowering medication No 316(69.45) 720(76.43) 69.5 0.005
Yes 139(30.55) 222(23.57) 61.5
Duration of diabetes in years. Mean [SD] 14.84[9.48] 16.95[10.32] NA <0.001
Glycated haemoglobin in 2013 Mean [SD] 7.16[1.35] 6.95[1.05] NA 0.003
Systolic blood pressure in 2013. Mean [SD] 130.8[13.04] 131.4[11.21] NA 0.256
Diastolic blood pressure in 2013. Mean [SD] 74.7[7.45] 73.3[7.19] NA <0.001
Total cholesterol in 2013. Mean [SD] 177.1[37.37] 170.9[32.22] NA <0.001
Body mass index in 2013. Mean [SD] 30.1[5.68] 29.8[5.17] NA 0.263
NA. Not applicable.
Table 3
Logistic regression multivariable model showing covariates independently associated with receiving influenza vaccination in year 2013.
Odds ratio Confidence interval 95% p-value
Age recommendation (P60 years) No 1 –
Yes 2.50 1.82–3.44 <0.001a
Chronic respiratory disease No 1 –
Yes 1.52 1.02–2.30 0.011
Previous pneumococcal vaccination No 1 –
Yes 2.54 1.83–3.55 0.004a
Number of visits to the GP in 2013 Continuous 1.05 1.01–1.09 0.003a
Number of influenza vaccines Continuous 1.29 1.10–1.57 <0.001a
Duration of diabetes in years Continuous 1.03 1.01–1.06 0.005a
Mean glycated haemoglobin in 2013 Continuous 0.83 0.75–0.93 <0.001a
a Significant using Alpha Bonferroni correction (0.05/7 = 0.007).
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show the marked effect that visiting one’s physician and the advice
of HCWs have on adherence to recommendations for vaccination
[17,18,20,21,23–28,33,34]. In our study, each visit to family physi-
cians in 2013 increased the probability of uptake by 5%. Further-
more, when asked the reason for being vaccinated, over 90% of
vaccinated persons replied that their physician had recommended
it to them due to their age or chronic conditions.
Vaccination is more likely in patients who use the healthcare
system more frequently. Lewis-Parmar and McCann [24] found
that if vaccination is recommended by HCWs, the probability that
a person with diabetes is vaccinated increases 14-fold, and that
this was the only source of information that led to an increase in
uptake [24].
The most common reasons given for not being vaccinated in the
present study were not perceiving themselves at risk for influenza
and concerns about adverse effects of the vaccine. These answerssuggest insufficient knowledge of the need for and safety of influ-
enza vaccine and are in line with results from both the general
population and people with T2DM [23,26,27,34]. HCWs should
take all available opportunities in their interactions with patients
to provide objective information about the risks of influenza and
the benefits of influenza vaccination and address all concerns that
patients have.
Several factors associated with HCWs and the organization of
healthcare services may also explain why too many diabetic
patients are not vaccinated against influenza [24,27,32,35]. First,
during daily routine diabetes care, the participating physicians
may not be sufficiently concerned about preventive measures in
patients with poor health outcomes owing to time constraints. Sec-
ond, since physicians are mostly concerned with the treatment of
presenting symptoms, they may forget to recommend preventive
measures such as vaccinations in their busy daily practice. Third,
physicians rarely track their patients’ vaccinations, thus potentially
Table 4
Reasons for receiving and not receiving influenza vaccine in the last campaign according to gender.
Gender
Male Female Total
n % n % n %
Reason for receiving the vaccination p-value = 0.049 Recommended by a physician because of my age 373 49.21 352 50.29 725 49.73
Recommended by a physician because of my chronic conditions 323 42.61 318 45.43 641 43.96
Vaccination in the work place 18 2.37 5 0.71 23 1.58
Own request 23 3.03 9 1.29 32 2.19
Other or don’t know 21 2.77 16 2.29 37 2.54
Reason for not being vaccinated p-value = 0.001 Not Recommended by a HCWs or health authorities 8 2.28 13 4.45 21 3.27
Not consider myself at risk 146 41.60 87 29.79 233 36.24
The vaccine is not effective. 36 10.26 20 6.85 56 8.71
Fear of adverse reactions 71 20.23 95 32.53 166 25.82
The vaccine can transmit the flu. 11 3.13 3 1.03 14 2.18
Flu is a benign illness. 11 3.13 8 2.74 19 2.95
Access difficulties (lack o time. distance to the health center). 22 6.27 14 4.79 36 5.60
Others 42 11.97 47 16.10 89 13.84
Don’t know 4 1.14 5 1.71 9 1.40
P value comparing male vs. female.
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organizational systems that could help to increase vaccine uptake
are not implemented.
Effective strategies for increasing influenza vaccination cover-
age in high-risk groups include the following: 1. Mass media pub-
licity to promote vaccination. 2. Information for HCWs and persons
with diabetes and their families about the risks of influenza and
prevention strategies. 3. Expanding access to health care settings.
4. Use of computerized reminders at the GP’s office. 5. Financial
incentives for physicians [24,32,34,36–38].
Expanding access to healthcare settings implies that access to
care must be acceptable to the patient, meaning services that are
respectful of the patients’ culture and values and promote patient
understanding and involvement in treatment decisions [36–38].
Access must include the availability of care in the patient’s com-
munity, with convenient hours to accommodate working families
including offering more out-of-hours appointments, waiting times
that do not discourage patients from seeking care, and appropriate
accommodations for vulnerable populations, such as home-based
services [36–38]. In home based programs, home visitors assess
patients’ vaccination status, discuss the importance of recom-
mended vaccinations, and either provide vaccinations to patients
in their homes or refer them to available immunization services
[38].
Systematic reviews and meta-analysis suggest that clinician
financial incentives are effective to improve influenza vaccination
coverages [39,40]. In the UK the success of the pay for performance
program has been demonstrated by high influenza vaccination
coverages among the elderly population and high risk groups for
suffering concomitant chronic conditions [41,42]. Norbury et al.,
using the general-practice population database in 15 general prac-
tices in Scotland analyzed the effectiveness of financial incentives
to GPs for influenza immunisation from the 2003/4 to the 2006/7
seasons. Among people with diabetes the vaccination coverage
raised significantly from 59.7–67.3% for those aged under 65 years
and the coverage remained unchanged and over 86% for those aged
65 years and more [42].
However possible barriers to implementation of such programs
would be ethical concerns about whether incentives constitute
coercion and doubts if pay-for-performance systems can con-
tribute to reduce health inequalities [43,44].
The Society of General Internal Medicine Ethics Committee
advocate four major strategies to warranty high quality health care
and ethical performance-based physician compensation. These are
1. Current pay-for-performance systems should rapidly adopt safe-guards to protect vulnerable populations. 2. Key stakeholders
should develop consensus regarding their responsibilities in
improving health care quality. 3. Researchers and policy makers
should develop valid and comprehensive quality measures for
use in the next generation of compensation systems that reward
genuine quality. 4. Researchers and policy makers should use a
cautious evaluative approach to long-term development of com-
pensation systems that reward quality [44].
Our study is subject to a series of limitations. First, the external
validity of these results is limited because the study population
may not be representative of the real population of patients with
diabetes. Second, some of our information was self-reported and
may therefore be prone to recall or social desirability biases. Third,
accurate determination of the reasons for refusing vaccination is
complicated, because the reasons can vary over time for the same
person. Fourth, variables not collected during the study included
the GP’s beliefs about risk of influenza and effectiveness of vaccina-
tion, which may play a role in uptake and therefore prevent us
from ruling out the possibility of residual confounding. Fifth, the
telephone survey was conducted in year 2013 and no other survey
has been done afterwards so we decided not to analyze vaccination
coverages for years 2014 and 2015. Finally, as the participation rate
for the survey was 79.2%, a potential selection bias must be taken
into consideration.
In conclusion, the uptake of influenza vaccination among
patients with T2DM in our population is below desirable levels.
Older patients and those who follow preventive practices control
their disease better and pay more visits to their GP are vaccinated
more frequently. The main barrier to vaccination is the lack of
knowledge regarding the need for and risks and the advantages
of influenza vaccination. HCWs should make every effort to edu-
cate patients and encourage influenza vaccination among people
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